Skip to main content

Table 2 Immune monitoring summary and clinical outcomes of patients who produced a measureable immune response

From: Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

Dose (mg) Patient HLA Type HLA/A*0101 Tetramer+ CD8+ IFNγ+ Phenotype Tetramer+CD8+T cells*
0.2 Tyr-1 A0101 - -  
Tyr-2 A1101 ND -  
Tyr-3 A01 ND -  
0.5 Tyr-4 A0101 - -  
Tyr-5 A0101 - -  
Tyr-6 A2501 ND -  
1.5 Tyr-8 A2402 ND -  
Tyr-9 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
Tyr-11 A0101 - -  
Tyr-12# A02 ND ND  
Tyr-13 A2402 ND -  
Tyr-14 A0301/A2402 ND -  
Tyr-16# A0101 ND ND  
Tyr-18 A0101 - -  
Tyr-19 A0101 - -  
Tyr-20# A0101 ND ND  
Tyr-21 A03 ND -  
Tyr-22 A0101 - -  
Tyr-23 A0101 - -  
Tyr-24 A0101 - +  
Tyr-25 A0101 - +  
Tyr-26 A0101 + + CCR7low,CD45RAlow, CD27int, CD28low
Tyr-27 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
Tyr-28 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
  1. * Low = 0–30%, intermediate (int) =30–60%, and high = 60–100% of cells that are tetramer positive. # Patient Tyr-12, 16 and 20 did not finish vaccine protocol. ND = not done. “+” = Patients scored positive for tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response; “-” = Patients scored negative for tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response.